The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.
The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. A secondary objective is to determine the mortality in this critically ill population of individuals. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.
Study Type
OBSERVATIONAL
Enrollment
134
all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
ACMT; ToxIC participating sites
Phoenix, Arizona, United States
University of Southern California
Los Angeles, California, United States
Survival
The primary objective is to compare survival based on lipophilicity (as measured by LogD) of the drugs
Time frame: Survival is measured at hospital discharge. The study is open to enrollment indefinitely. It is estimated approximately 100 subjects will be enrolled in 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.